Saydam, Guray; Ali, Ridvan; Demir, Ahmet Muzaffer; Eskazan, Ahmet Emre; Guvenc, Birol; Haznedaroglu, Ibrahim Celalettin; Ozcan, Mehmet Ali; Salim, Ozan; Sonmez, Mehmet; Tuglular, Ayse Tulin; Turgut, Mehmet; Unal, Ali; Aver, Birkan; Bozkurt, Sirac; Ozdengulsun, Begum; Ilhan, Osman published an article in 2022, the title of the article was The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.HPLC of Formula: 380843-75-4 And the article contains the following content:
A review. Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the most up-to-date data and provides practical recommendations for clin. approaches. Nilotinib and ponatinib should be avoided in patients with cardiovascular risk factors, dasatinib in patients with lung damage and bosutinib and nilotinib in patients with liver disease. Considering that certain comorbidities predispose some patients to developing severe adverse events when receiving TKIs, the first- and second-line treatment of chronic myeloid leukemia should be tailored to each patient’s individual condition. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).HPLC of Formula: 380843-75-4
The Article related to review chronic myeloid leukemia comorbidity tki nilotinib ponatinib dasatinib, adverse event, chronic myeloid leukemia, comorbidity, drug toxicity, interactions (drug–drug), safety, tolerability, tyrosine kinase inhibitor and other aspects.HPLC of Formula: 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics